Received Oct 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
developed Guillian-Barre after receiving Shingrix.; This serious case was reported by a consumer and described the occurrence of guillain barre syndrome in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced guillain barre syndrome (Verbatim: developed Guillian-Barre after receiving Shingrix.) (serious criteria GSK medically significant). The outcome of the guillain barre syndrome was resolved. The reporter considered the guillain barre syndrome to be related to Shingrix. The company considered the guillain barre syndrome to be unrelated to Shingrix. Additional Information: GSK receipt date: 18-OCT-2025 The patient self-reported this case. The patient was injured from the Shingrix vaccine that gave guillain barre syndrome. The batch number was not provided, and unable to contact the reporter.; Sender's Comments: A case of Guillain-Barre syndrome, an unknown time after receiving Shingrix, in a patient. Based on the available information a possible causality that the event was caused by GSK vaccine product cannot be ascertained. Consent for further follow up has not been received.